A Phase IIA Randomised, Double-blind, Double Dummy, Placebo and Active Controlled 5-Way Cross-over Trial to Examine the Bronchodilator Effects of PF-610,355 and to Test for Superiority Versus Placebo in Reversible Asthmatic Patients.

Trial Profile

A Phase IIA Randomised, Double-blind, Double Dummy, Placebo and Active Controlled 5-Way Cross-over Trial to Examine the Bronchodilator Effects of PF-610,355 and to Test for Superiority Versus Placebo in Reversible Asthmatic Patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Jan 2014

At a glance

  • Drugs PF 610355 (Primary) ; Salmeterol
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 15 Sep 2009 Results presented at the 19th Annual Congress of the European Respiratory Society (ERS-2009).
    • 30 Nov 2007 Status changed from in progress to completed.
    • 14 Nov 2007 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top